Buying tirzepatide online: what TikTok skips over

What's this video probably claiming?

Based on the caption, @sarabarcenas8 appears to be telling followers where she personally buys tirzepatide, framing it as a casual, relatable recommendation. The hashtag flaca (Spanish slang for "skinny girl") and the Tirzepatide Girly branding suggest the video positions tirzepatide as a straightforward weight-loss tool, something any woman can just go buy. The phrase "aquí los compro" ("this is where I buy them") is a direct purchasing referral, not a medical discussion. At 3.6K views, this is exactly the kind of mid-tier influencer content that quietly normalizes sourcing prescription medications outside of a clinical setting, no doctor mentioned, no diagnosis mentioned, no monitoring protocol mentioned. The tone is aspirational and aesthetic, which is a deliberate framing choice that papers over the regulatory and safety complexity involved in actually using this drug.

What does the science actually show?

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for chronic weight management (Zepbound). The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on 15 mg weekly tirzepatide lost an average of 20.9% of body weight over 72 weeks, compared to 3.1% with placebo. That is a genuinely impressive number. But that trial also had structured medical supervision, regular monitoring, and specific inclusion criteria. Participants were adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. The drug works, but "it works" is not the same as "anyone should buy it from an Instagram link and self-administer it." The mechanism is real. The results are real. The context in which those results were achieved is being quietly omitted from videos like this one.

Where does the social media noise diverge from clinical reality?

The biggest divergence is around sourcing. Tirzepatide is a Schedule V controlled substance analog in some states, and unregulated compounded tirzepatide has been a persistent problem. The FDA issued warnings in 2024 about compounded tirzepatide products containing tirzepatide acetate rather than tirzepatide base, with different pharmacokinetic properties and unknown safety profiles. Buying from an unlicensed or unverified source means you have no idea what you are actually injecting. Beyond sourcing, the side effect profile gets almost zero airtime in aesthetic influencer content. The SURMOUNT trials documented nausea in 30-45% of participants, vomiting in 15-25%, and more serious risks including potential thyroid C-cell effects, pancreatitis, and gallbladder disease. These are not rare edge cases. They are listed in the drug's FDA label because they showed up consistently in clinical data. Self-dosing without a prescriber also means no titration guidance, which is how adverse events escalate.

What should you actually know?

Tirzepatide is a legitimate, well-studied medication with meaningful clinical evidence behind it. That is not in dispute. What is in dispute is the framing that you can casually buy it online from a social media recommendation and expect the same outcomes as a monitored clinical trial. If you are considering tirzepatide for weight management, you need a licensed prescriber who can assess your cardiovascular history, thyroid history, gastrointestinal baseline, and concurrent medications. You need a titration schedule, starting doses are typically 2.5 mg weekly before stepping up. And you need a source that can verify what is actually in the product. Compounded tirzepatide from a state-licensed 503A or 503B pharmacy operating under a valid prescription is a different situation from buying from a TikTok referral link. The drug's efficacy does not transfer to an unverified product. The FDA's shortage-era enforcement discretion for compounded GLP-1s was also narrowed in 2024, so the legal landscape for compounders is shifting quickly.